JP2019511904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511904A5 JP2019511904A5 JP2018539977A JP2018539977A JP2019511904A5 JP 2019511904 A5 JP2019511904 A5 JP 2019511904A5 JP 2018539977 A JP2018539977 A JP 2018539977A JP 2018539977 A JP2018539977 A JP 2018539977A JP 2019511904 A5 JP2019511904 A5 JP 2019511904A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- seq
- ror1
- binding
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000023732 binding proteins Human genes 0.000 claims description 126
- 108091008324 binding proteins Proteins 0.000 claims description 126
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 65
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 64
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 239000000523 sample Substances 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 32
- 230000009870 specific binding Effects 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 238000011467 adoptive cell therapy Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 102000049583 human ROR1 Human genes 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 24
- 238000009169 immunotherapy Methods 0.000 description 8
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 201000005249 lung adenocarcinoma Diseases 0.000 description 5
- 208000000649 small cell carcinoma Diseases 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 5
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021196080A JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290337P | 2016-02-02 | 2016-02-02 | |
| US62/290,337 | 2016-02-02 | ||
| US201662324876P | 2016-04-19 | 2016-04-19 | |
| US62/324,876 | 2016-04-19 | ||
| PCT/US2017/016300 WO2017136607A1 (en) | 2016-02-02 | 2017-02-02 | Anti-ror1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196080A Division JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511904A JP2019511904A (ja) | 2019-05-09 |
| JP2019511904A5 true JP2019511904A5 (enExample) | 2020-03-12 |
| JP7029401B2 JP7029401B2 (ja) | 2022-03-03 |
Family
ID=58054529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10968275B2 (enExample) |
| EP (2) | EP4006056A1 (enExample) |
| JP (2) | JP7029401B2 (enExample) |
| CN (1) | CN108699149B (enExample) |
| AU (1) | AU2017213844A1 (enExample) |
| CA (1) | CA3012827A1 (enExample) |
| ES (1) | ES2903228T3 (enExample) |
| MX (1) | MX2018009011A (enExample) |
| WO (1) | WO2017136607A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| JP7029401B2 (ja) | 2016-02-02 | 2022-03-03 | フレッド ハッチンソン キャンサー リサーチ センター | 抗ｒｏｒ１抗体およびその使用 |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP3936523A4 (en) * | 2019-01-08 | 2022-09-07 | Shenzhen University | DETECTION OF ANTIBODIES AGAINST MALIGNANT TUMOR CELLS AND THEIR USES |
| EA202192103A1 (ru) | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CN118974090A (zh) * | 2022-04-02 | 2024-11-15 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| IL318546A (en) * | 2022-07-26 | 2025-03-01 | Aimed Bio Inc | Anti-ROR1 antibody and its uses |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115894691B (zh) * | 2022-12-27 | 2026-03-03 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| EP4647445A1 (en) * | 2022-12-27 | 2025-11-12 | SPH Biotherapeutics (Shanghai) Limited | Antigen-binding proteins targeting ror1 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| JP2026526141A (ja) * | 2023-07-04 | 2026-08-06 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | 抗ｒｏｒ１抗体およびその使用 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026112136A2 (en) | 2024-11-20 | 2026-05-28 | Immunome, Inc. | Methods of treating cancer with anti-ror1 antibody drug conjugates |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
| CA138293A (en) | 1911-11-06 | 1912-02-06 | Charles E. Archie | Variable speed gearing |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2003218456A1 (en) | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| SI1680140T1 (sl) | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
| EP1786463A4 (en) | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
| PL2305300T3 (pl) | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US9316646B2 (en) | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
| US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2741770A4 (en) | 2011-08-09 | 2014-12-31 | Athera Biotechnologies Ab | ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES |
| AP2014007588A0 (en) | 2011-09-22 | 2014-04-30 | Amgen Inc | CD27L antigen binding proteins |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| HK1220614A1 (zh) | 2013-03-10 | 2017-05-12 | Baylor College Of Medicine | 耐化疗免疫细胞 |
| US10752684B2 (en) | 2014-07-29 | 2020-08-25 | Cellectis | ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| JP7029401B2 (ja) | 2016-02-02 | 2022-03-03 | フレッド ハッチンソン キャンサー リサーチ センター | 抗ｒｏｒ１抗体およびその使用 |
| WO2017214207A2 (en) | 2016-06-06 | 2017-12-14 | Juno Therapeutics, Inc. | Methods for the treatment of b cell malignancies using adoptive cell therapy |
-
2017
- 2017-02-02 JP JP2018539977A patent/JP7029401B2/ja active Active
- 2017-02-02 AU AU2017213844A patent/AU2017213844A1/en not_active Abandoned
- 2017-02-02 MX MX2018009011A patent/MX2018009011A/es unknown
- 2017-02-02 US US16/074,737 patent/US10968275B2/en active Active
- 2017-02-02 CA CA3012827A patent/CA3012827A1/en active Pending
- 2017-02-02 EP EP21204990.2A patent/EP4006056A1/en active Pending
- 2017-02-02 CN CN201780009313.5A patent/CN108699149B/zh active Active
- 2017-02-02 EP EP17705745.2A patent/EP3411408B1/en active Active
- 2017-02-02 WO PCT/US2017/016300 patent/WO2017136607A1/en not_active Ceased
- 2017-02-02 ES ES17705745T patent/ES2903228T3/es active Active
-
2021
- 2021-01-25 US US17/157,810 patent/US11932691B2/en active Active
- 2021-12-02 JP JP2021196080A patent/JP2022028918A/ja active Pending
-
2024
- 2024-02-07 US US18/435,933 patent/US20240352119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022028918A5 (enExample) | ||
| JP7029401B2 (ja) | 抗ｒｏｒ１抗体およびその使用 | |
| DK3054298T3 (en) | METHOD OF DETECTING TUMOR IN THE ARC | |
| CN107098970B (zh) | 结合细胞内prl-1多肽或prl-3多肽的抗体 | |
| JP6244911B2 (ja) | 癌の検出方法 | |
| JP2015517982A5 (enExample) | ||
| DK2743697T3 (en) | METHODS OF IN VITRO DIAGNOSTICS OF INVASIVE CARCINOMS | |
| Ho | Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin | |
| CN108025064A (zh) | 抗磷脂酰肌醇蛋白聚糖-3抗体和其用于诊断与治疗癌症的用途 | |
| JP2020143122A (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| US9815906B2 (en) | Method of inhibiting or treating cancer metastasis | |
| US20220308059A1 (en) | Biomarkers for disease progression in squamous cell carcinoma | |
| KR102350259B1 (ko) | Igf-1r 항체 및 암의 진단을 위한 그의 용도 | |
| Shapiro et al. | Identification of tumor antigen af20 as glycosylated transferrin receptor 1 in complex with heat shock protein 90 and/or transporting atpase | |
| RU2019112825A (ru) | Моноклональное антитело против fzd10, его использование | |
| WO2020225547A1 (en) | Methods of determining the margin of a tumour | |
| RU2493166C1 (ru) | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка | |
| Marzouq et al. | Production of Recombinant Human EGFR CR2 Domain and Generation of Monoclonal Antibodies Discriminating The R and K Variants. | |
| CA2714880C (en) | A novel tumor biomarker | |
| CN119912570A (zh) | 一种抗trbc1纳米抗体及其制备方法与应用 | |
| JP2011144124A (ja) | 活性型ｅｇｆｒ特異抗体 | |
| EP3948287A1 (en) | Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods | |
| HK1165475A (en) | In tumours differentially expressed gene products and use of the same |